FMP
May 28, 2025
iTeos Therapeutics Inc. (NASDAQ: ITOS) shares jumped 21% after the board announced it will cease clinical operations and pursue the sale of key assets to maximize near-term shareholder value.
The decision follows a thorough review of iTeos's pipeline, financial position, and business prospects. Key assets up for sale include:
EOS-984: Lead immuno-oncology candidate
EOS-215: Second-generation checkpoint inhibitor
Preclinical ENT1 Obesity Program
Management aims to leverage the company's cash balance and intellectual property proceeds to deliver returns, signaling a pivot from R&D to asset monetization.
As of its latest filings, iTeos holds a robust cash runway that underpins its ability to execute asset sales without external financing. Investors can track iTeos's credit profile and liquidity metrics in real time via the Company Rating API, ensuring visibility into how winding down operations affects its debt capacity.
The surprise wind-down announcement sparked a significant stock rally, reflecting optimism around sale proceeds. To monitor evolving analyst expectations and any revisions to price targets, consult the Price Target Summary API, which aggregates consensus forecasts and target changes for ITOS and its peers.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...